|1.||Tracey, K J: 5 articles (12/2001 - 07/2000)|
|2.||Al-Abed, Yousef: 4 articles (01/2015 - 07/2008)|
|3.||Hauber, Joachim: 3 articles (01/2012 - 05/2008)|
|4.||Plasse, Terry: 3 articles (06/2010 - 01/2002)|
|5.||Tracey, Kevin J: 3 articles (01/2006 - 03/2002)|
|6.||Symons, Marc: 2 articles (01/2015 - 01/2014)|
|7.||Bacher, Michael: 2 articles (01/2013 - 07/2008)|
|8.||Kaiser, Annette: 2 articles (01/2012 - 05/2008)|
|9.||Hauber, Ilona: 2 articles (05/2011 - 05/2008)|
|10.||Meier, Chris: 2 articles (05/2011 - 05/2008)|
07/01/2011 - "Semapimod significantly reduced this inflammation and improved gastric emptying. "
03/01/2005 - "Treatment with CNI-1493 provides efficient protection against synovial inflammation and cartilage destruction when used therapeutically in CIA. "
01/01/2004 - "The tetravalent guanylhydrazone CNI-1493 (CNI-1493) has been shown to inhibit macrophage activation, reduce systemic inflammation as well as proinflammatory cytokine production. "
03/18/2002 - "Vagus nerve firing is also stimulated by CNI-1493, a tetravalent guanylhydrazone molecule that inhibits systemic inflammation. "
04/30/1996 - "Identification of the molecular target through which CNI-1493 inhibits TNF translation should provide insight into the regulation of macrophage activation and mechanisms of inflammation."
|2.||Septic Shock (Toxic Shock Syndrome)
10/01/1999 - "There was significantly improved survival and cytokine inhibition in the endotoxic shock model as well as the peritonitis model in rats treated with microencapsulated CNI-1493. "
01/01/2010 - "Synergism in survival to endotoxic shock in rats given microencapsulated CNI-1493 and antisense oligomers to NF-kappaB."
10/01/1999 - "Prevention of lethality and suppression of proinflammatory cytokines in experimental septic shock by microencapsulated CNI-1493."
10/01/1999 - "Microencapsulated CNI-1493 was also given to rats with endotoxic shock (15 mg/kg Escherichia coli endotoxin) and rats with peritonitis induced by peritoneally injecting 10(10) CFU E. "
01/01/2010 - "Previous studies have demonstrated that targeting macrophages and other phagocytic cells by intracellular drug delivery using albumin microcapsules containing either antisense oligomers to NF-kappaB or CNI-1493 greatly enhances intracellular drug concentration and survival in both endotoxic shock and sepsis models. "
08/01/2008 - "This study evaluated whether intravenous (IV) administration of semapimod given before an ERCP reduces the incidence of post-ERCP hyperamylasemia and pancreatitis. "
08/01/2008 - "A single dose of IV semapimod 1 hour before an ERCP is safe and exerts a biological effect, demonstrated by a statistically significant reduction of the incidence of hyperamylasemia and the levels of post-ERCP amylase. "
08/01/2008 - "Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence."
03/01/2005 - "Clinical signs of arthritis were significantly reduced in the CNI-1493 treated group of rats in comparison with the placebo treated group. "
03/01/2005 - "In a placebo controlled experiment, CNI-1493 was given once daily intraperitoneally after onset of clinical arthritis in DA rats. "
03/01/2005 - "These observations make CNI-1493 an attractive candidate for therapeutic studies in human arthritis, and COMP an attractive serum marker for monitoring joint protective effects."
|5.||Crohn Disease (Crohn's Disease)
08/15/2005 - "Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease."
01/01/2012 - "Target evaluation of parasitic DHS has recently been performed with CNI-1493, a novel selective pro-inflammatory cytokine inhibitor used in clinical phase II for the treatment of Crohn's disease. "
06/01/2010 - "Semapimod, a small molecule known to inhibit proinflammatory cytokine activity, was studied to determine the optimal dose necessary to achieve a response in patients with moderate to severe Crohn's disease (CD). "
06/01/2010 - "A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease."
05/01/2008 - "In a screen for new inhibitors of purified plasmodium DHS, CNI-1493, a novel selective pro-inflammatory cytokine inhibitor used in clinical phase II for the treatment of Crohn's disease, inhibited the enzyme of the parasite 3-fold at a concentration of 2 microM. "
|2.||Biological Markers (Surrogate Marker)
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|7.||Interleukin-6 (Interleukin 6)
|8.||Protein Kinases (Protein Kinase)
|4.||Homologous Transplantation (Allograft)
|5.||Heterologous Transplantation (Xenotransplantation)